BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv6.5.5//EN
X-ORIGINAL-URL:https://fokuspatient.se/
X-WR-CALNAME:Fokus Patient
X-WR-CALDESC:- Alltid patienten i fokus
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
DTSTART;TZID=Europe/Stockholm:20210713T140000
DTEND;TZID=Europe/Stockholm:20210713T150000
DTSTAMP:20210706T095400
UID:MEC-edb947f2bbceb132245fdde9c59d3f59@fokuspatient.se
CREATED:20210706
LAST-MODIFIED:20210706
PRIORITY:5
TRANSP:OPAQUE
SUMMARY:Improving Europe’s Health Technology Assessments
DESCRIPTION:\n\nEurope’s health care systems aren’t feeling very well–something the current pandemic isn’t improving -and Health Technology Assessments (HTAs) are at the heart of the strategy to improve their quality, efficiency,and sustainability. They have been put in place to move towards a more value-based and evidence-driven decision-making in health care, concerning everything from pharmaceuticals to devices and procedures.\nWhile HTAs are key in ensuring new drugs and medical devices deliver meaningful innovation for patients and good value for money for health systems, cooperation between the more than 50 HTA bodies in the EU is still voluntary. The European Commission’s proposal to strengthen HTA cooperation between members states has been mired in talks since it was first put forward in 2018 —but trialogues with the Parliament and Council have finally reached an informal deal. If planned out successfully, this text could open the door to more cooperation, more efficiency, and a less fragmented internal market –resulting in a more competitive sector, and a fairer access to valuable drugs across the EU.\nThe negotiations on HTA cooperation in the EU are also a good opportunity to look at HTA processes more broadly: what works well, what needs to be improved to make them future proof, what are the best practices in the EU and how they can be used to improve HTAs across the bloc.\nMain questions for discussion include:\n\nWhat were the sticking points in HTA negotiations and why? If cooperation is not mandatory, what are its concrete benefits? How would greater collaboration across member states improve HTA processes?\n\n\nAnd how is the regulation as it stands now fulfilling its objectives of improving patient access to innovation, ensuring the efficiency and quality of HTA resources, and improving business predictability1? What could it do better?\n\n\nWhat is the public health cost and impact on patients of the delay on the HTA deal, particularly in countries who stand to benefit the most from cooperation?\n\n\nPatient involvement in HTAs vary widely across Europe, even though they are directly impacted by the decisions. What role can the EU play in further incentivizing and streamlining meaningful patient involvement in HTA processes?\n\n\nSome therapies do not go through an HTA procedure. What are the lessons learned when it comes to putting on the market products without assessing their added value first?\n\n\nWhat has the past year highlighted on the use of real-world data and real-world evidence in health decision-making? Could this mean more widespread use of RWD/RWD in HTAs process –like in Germany for instance –throughout the EU? Do systems have the data and interoperability to do so?\n\n\n\n#PoliticoHTA\nRegister:\nhttps://www.politico.eu/event/registration/1678763/  ( https://www.politico.eu/event/registration/1678763/ )\n\n\n\n\n\n\n\n\n\n
URL:https://fokuspatient.se/events/improving-europes-health-technology-assessments/
ATTACH;FMTTYPE=image/jpeg:https://fokuspatient.se/wp-content/uploads/2021/07/Improving-Europes-Health-Technology-As-2320x400px-1320x228-1.jpg
END:VEVENT
END:VCALENDAR